Concepedia

Author

Bruno Gomes

InsermORCID

Also Known As

B Gomes, B. Gomes, B.M. Gomes, B.M.S. Gomes, Bernardo Filipe Santos Gomes, Bruno GOMES, Bruno Gomes, Bruno Mattiello Gomes, F. Yu, Gomes, Bruno

84

Publications

949

Citations

13

H-Index

32

Concepts

All Affiliations

InsermPierre Fabre (France)Bone TherapeuticsRoche Pharma AG (Germany)University Health Network
BG

About

Bruno Gomes is an author at Inserm specializing in medicine, tumor biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

8

8

353

2

Immunology

2

2

56

3

Health Sciences

1

1

35

4

Allergy

1

1

25

5

Cell Biology

1

1

109

Bruno Gomes

×

17

Publications

771

Citations

13

H-Index

YearCitations

Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1<i>H</i>-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate

Stefano Crosignani, Patrick Bingham, Pauline Bottemanne,

Journal of Medicinal Chemistry

2017

134

Static lung storage at 10°C maintains mitochondrial health and preserves donor organ function

Aadil Ali, Aizhou Wang, Rafaela Vanin Pinto Ribeiro,

Science Translational Medicine

2021

117

Melanoma Chemotherapy Leads to the Selection of ABCB5-Expressing Cells

Marine Chartrain, Joëlle Riond, Aline Stennevin,

PLoS ONE

2012

109

Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma

Laurent Créancier, Isabelle Vandenberghe, Bruno Gomes,

Cancer Letters

2015

90

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Grégory Driessens, Derek W. Bartlett,

Molecular Cancer Therapeutics

2018

83

Anticancer activity of koningic acid and semisynthetic derivatives

Nicolas J. Rahier, Nicolas Molinier, Christophe Long,

Bioorganic & Medicinal Chemistry

2015

37

F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity

Anna Kruczynski, Arnaud Pillon, Laurent Créancier,

Leukemia

2013

35

Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology

Rima Ait-Belkacem, Vanesa Bol, Grégory Hamm,

SLAS DISCOVERY

2017

31

Abstract 4863: PF-06840003: a highly selective IDO-1 inhibitor that shows good in vivo efficacy in combination with immune checkpoint inhibitors

Joseph R. Tumang, Bruno Gomes, Martin Wythes,

Cancer Research

2016

25

Analysis of Spatial Organization of Suppressive Myeloid Cells and Effector T Cells in Colorectal Cancer—A Potential Tool for Discovering Prognostic Biomarkers in Clinical Research

Natalie Zwing, Henrik Failmezger, Chia-Huey Ooi,

Frontiers in Immunology

2020

24

Page 1